Current and Future Standards in Treatment of Myasthenia Gravis

Neurotherapeutics

Volumn 5, Issue 4, 2008, Pages 535-541

  Gold, Ralf ^a   Schneider Gold, Christiane ^a  

^a ST JOSEF HOSPITAL   (Germany)

Author keywords

acetylcholine receptor; immunoadsorption; immunoglobulins; Immunosuppression; muscle specific kinase; plasmapheresis; thymoma

Indexed keywords

ALLOPURINOL; ATACICEPT; AZATHIOPRINE; CD20 ANTIBODY; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; GLUCOCORTICOID; IMMUNOGLOBULIN G; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OFATUMUMAB; PLACEBO; PREDNISONE; PYRIDOSTIGMINE; RITUXIMAB; TACROLIMUS; UNCLASSIFIED DRUG;

ARTICLE; ASEPTIC MENINGITIS; BEDTIME DOSAGE; CATARACT; CLINICAL TRIAL; CONTINUOUS INFUSION; CUSHING SYNDROME; DIABETES MELLITUS; DIGESTIVE SYSTEM ULCER; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEVER; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEPATITIS; HIRSUTISM; HUMAN; HYPERTENSION; IMMUNOADSORPTION; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY FAILURE; LEUKOPENIA; LIVER TOXICITY; LYMPHOMA; MALAISE; MYASTHENIA GRAVIS; NAUSEA AND VOMITING; NEPHROTOXICITY; NONHODGKIN LYMPHOMA; OBESITY; OPPORTUNISTIC INFECTION; OSTEOPOROSIS; PLASMAPHERESIS; POTASSIUM DEPLETION; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; SEPSIS; SIDE EFFECT; SKIN MANIFESTATION; TERATOGENICITY; THYMECTOMY; TREMOR; WEIGHT GAIN;

EID: 53049086856     PISSN: 19337213     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nurt.2008.08.011     Document Type: Article

References (35)

1. Drachman D.B. Myasthenia gravis. N Engl J Med 330 (1994) 1797-1810
2. Hohlfeld R., and Wekerle H. The immunopathogenesis of myasthenia gravis. In: Engel A.G. (Ed). Myasthenia gravis and myasthenic syndromes (1999), Oxford University Press, Oxford 87-110
3. Vincent A., Bowen J., Newsom-Davis J., and McConville J. Seronegative generalised myasthenia gravis: clinical features, antibodies and their targets. Lancet Neurol 2 (2003) 99-106
4. Hohlfeld R., Melms A., Schneider C., Toyka K.V., and Drachman D.B. Therapy of myasthenia gravis and myasthenic syndromes. In: Brandt T., Caplan L.R., Dichgans J., Diener H.C., and Kennard C. (Eds). Neurological disorders: course and treatment (2003), Elsevier, Philadelphia 1341-1362
5. Wekerle H., and Ketelsen U.P. Intrathymic pathogenesis and dual genetic control of myasthenia gravis. Lancet 1 (1977) 678-680
6. Kirchner T., Schalke B., Melms A., von Kugelgen T., and Muller-Hermelink H.K. Immunohistological patterns of non-neoplastic changes in the thymus in Myasthenia gravis. Virchows Arch B Cell Pathol Incl Mol Pathol 52 (1986) 237-257
7. Farrugia M.E., Robson M.D., Clover L., et al. MRI and clinical studies of facial and bulbar muscle involvement in MuSK antibody-associated myasthenia gravis. Brain 129 (2006) 1481-1492
8. Leite M.I., Strobel P., Jones M., et al. Fewer thymic changes in MuSK antibody-positive than in MuSK antibody-negative MG. Ann Neurol 57 (2005) 444-448
9. Strobel P., Bauer A., Puppe B., et al. Tumor recurrence and survival in patients treated for thymomas and thymic squamous cell carcinomas: a retrospective analysis. J Clin Oncol 22 (2004) 1501-1509
10. Schneider-Gold C., and Toyka K.V. Myasthenia gravis: pathogenesis and immunotherapy. (English). Dtsch Ärzteblatt 104 (2007) A420-A426
11. Gold R., Dalakas M.C., and Toyka K.V. Immunotherapy in autoimmune neuromuscular disorders. Lancet Neurol 2 (2003) 22-32
12. Muller-Hermelink H.K., and Marx A. Thymoma. Curr Opin Oncol 12 (2000) 426-433
13. Schneider-Gold C., Gajdos P., Toyka K.V., and Hohlfeld R.R. Corticosteroids for myasthenia gravis. Cochrane Database Syst Rev (2005) CD002828
14. Gronseth G.S., and Barohn R.J. Practice parameter: thymectomy for autoimmune myasthenia gravis (an evidence-based review)-Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 55 (2000) 7-15
15. Mertens H.G., Hertel G., Reuther P., and Ricker K. Effect of immunosuppressive drugs (azathioprine). Ann N Y Acad Sci 377 (1981) 691-699
16. Palace J., Newsom-Davis J., Lecky B., and Myasthenia Gravis Study Group. A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Neurology 50 (1998) 1778-1783
17. Gold R., and Toyka K.V. Immuntherapie neurologischer Erkrankungen (2006), UniMed Verlag, Bremen
18. Hohlfeld R., Toyka K.V., Besinger U.A., Gerhold B., and Heininger K. Myasthenia gravis: reactivation of clinical disease and of autoimmune factors after discontinuation of long-term azathioprine. Ann Neurol 17 (1985) 238-242
19. Schneider-Gold C., Hartung H.P., and Gold R. Mycophenolate mofetil and tacrolimus: new therapeutic options in neuroimmunological diseases. Muscle & Nerve 34 (2006) 284-291
20. Benatar M., and Rowland L.P. The muddle of mycophenolate mofetil in myasthenia. Neurology 71 (2008) 390-391
21. Schneider C., Gold R., Reiners K., and Toyka K.V. Mycophenolate mofetil in the therapy of severe myasthenia gravis. Eur Neurol 46 (2001) 79-82
22. Sanders D.B., Hart I.K., Mantegazza R., et al. An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis. Neurology 71 (2008) 400-406
23. Gold R., Stangel M., and Dalakas M.C. Drug insight: the use of intravenous immunoglobulin in neurology-therapeutic considerations and practical issues. Nat Clin Pract Neurol 3 (2007) 36-44
24. Gajdos P., Chevret S., Clair B., Tranchant C., and Chastang C. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Ann Neurol 41 (1997) 789-796
25. Gajdos P., Tranchant C., Clair B., et al. Treatment of myasthenia gravis exacerbation with intravenous immunoglobulin-a randomized double-blind clinical trial. Arch Neurol 62 (2005) 1689-1693
26. Zinman L., Ng E., and Bril V. IV immunoglobulin in patients with myasthenia gravis-a randomized controlled trial. Neurology 68 (2007) 837-841
27. Lehmann H.C., Hartung H.P., Hetzel G.R., Stuve O., and Kieseier B.C. Plasma exchange in neuroimmunological disorders: part 2. Treatment of neuromuscular disorders. Arch Neurol 63 (2006) 1066-1071
28. Bufler J., Kahlert S., Tzartos S., Toyka K.V., Maelicke A., and Franke C. Activation and blockade of mouse muscle nicotinic channels by antibodies directed against the binding site of the acetylcholine receptor. J Physiol (Lond) 492 (1996) 107-114
29. Heininger K., Hartung H.-P., Toyka K.V., Gaczkowski A., and Borberg H. Therapeutic plasma exchange in myasthenia gravis: semiselective adsorption of Anti-AChR autoantibodies with tryptophane-linked polyvinylalcohol gels. Ann N Y Acad Sci 505 (1987) 898-900
30. Flachenecker P., Taleghani B.M., Gold R., Grossmann R., Wiebecke D., and Toyka K.V. Treatment of severe myasthenia gravis with protein A immunoadsorption and cyclophosphamide. Transfus Sci 19 Suppl (1998) 43-46
31. Hauser S.L., Waubant E., Arnold D.L., et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 358 (2008) 676-688
32. Martin F., and Chan A.C. B cell immunobiology in disease: evolving concepts from the clinic. Annu Rev Immunol 24 (2006) 467-496
33. Chan A., Lee D.H., Linker R., Mohr A., Toyka K.V., and Gold R. Rescue therapy with anti-CD20 treatment in neuroimmunologic breakthrough disease. J Neurol 254 (2007) 1604-1606
34. Thakre M., Inshasi J., and Marashi M. Rituximab in refractory MuSK antibody myasthenia gravis. J Neurol 254 (2007) 968-969
35. Hain B., Jordan K., Deschauer M., and Zierz S. Successful treatment of musk antibody-positive myasthenia gravis with rituximab. Muscle & Nerve 33 (2006) 575-580